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Abstract
Background:  While the functional consequences of acute pulmonary infections are widely
documented, few studies focused on chronic pneumonia. We evaluated the consequences of
chronic Pseudomonas lung infection on alveolar function.
Methods: P. aeruginosa, included in agar beads, was instilled intratracheally in Sprague Dawley rats.
Analysis was performed from day 2 to 21, a control group received only sterile agar beads.
Alveolar-capillary barrier permeability, lung liquid clearance (LLC) and distal alveolar fluid clearance
(DAFC) were measured using a vascular (131I-Albumin) and an alveolar tracer (125I-Albumin).
Results: The increase in permeability and LLC peaked on the second day, to return to baseline on
the fifth. DAFC increased independently of TNF-α or endogenous catecholamine production.
Despite the persistence of the pathogen within the alveoli, DAFC returned to baseline on the 5th
day. Stimulation with terbutaline failed to increase DAFC. Eradication of the pathogen with
ceftazidime did not restore DAFC response.
Conclusions: From these results, we observe an adequate initial alveolar response to increased
permeability with an increase of DAFC. However, DAFC increase does not persist after the 5th day
and remains unresponsive to stimulation. This impairment of DAFC may partly explain the higher
susceptibility of chronically infected patients to subsequent lung injury.
Introduction
Pseudomonas aeruginosa is a Gram negative bacteria pro-
ducing a wide array of virulence factors frequently respon-
sible for chronic airway infections in cystic fibrosis (CF) or
chronic obstructive pneumonia disease (COPD) patients,
as well as acute nosocomial airway infections in intensive
care units [1-3].
In acute P. aeruginosa pneumonia, the functional conse-
quences, and particularly lung fluid movements, have
been studied extensively. Lung fluid balance is the result
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of fluid movements following active ion transport by
functional alveolar cells, and permeability of the alveolar
capillary barrier. In P. aeruginosa-induced acute lung
injury (ALI), distal airspace fluid clearance (DAFC) is typ-
ically increased at 24 hours through a TNF-α pathway [4].
Studies have also shown that the capacity of maintaining
alveolar active fluid transport is correlated with patient
outcome in ALI [5,6]. Lung liquid clearance (LLC) is
another functional marker reflecting the capacity of the
lung to evacuate fluid instilled in the alveoli outside the
lung, LLC involves DAFC, epithelial and endothelial per-
meabilities [7]. We previously showed that, even though
DAFC is upregulated, LLC is decreased at both 4 and 24
hours in ALI [7] reflecting a major endothelial injury over-
whelming the alveolar response.
In chronic infection, these functional consequences on
lung fluid balance are less clear. In the 70's, Cash devel-
oped an experimental model of chronic pneumonia by
intra tracheal injection of P. aeruginosa embedded in agar
beads [8]. Most of the work performed with this model
has focused on immunological, inflammatory, or nutri-
tional aspects [9-12]. To the best of our knowledge, no
previous work has tried to evaluate alveolar permeability
and lung fluid transport in P. aeruginosa chronic lung
infection. In order to elucidate these functional aspects we
studied lung fluid transport in an experimental model of
chronic P. aeruginosa lung infection in the rat. After the
validation of the experimental model, we studied alveolar
function: alveolar-capillary barrier permeability, lung liq-
uid clearance, distal airspace fluid clearance and its phar-
macologic stimulation.
Materials and Methods
Animals
Specific pathogen-free Sprague Dawley rats (n = 280)
(230–270 g), (Depre, St Doulchard, France) were housed
in the Lille University Animal Care Facility and allowed
food and water ad lib. All experiments were performed
with approval of the Lille Institutional Animal Care and
Use Committee.
Preparation of the bacterial inoculum
The methodology was adapted from Cash et al [8]. Briefly,
P. aeruginosa (PAO1 strain) was incubated in 125 ml of
tryptic soy broth at 37°C in a rotating shaking water bath
for 8 hours. The culture was then washed twice, and resus-
pended in phosphate-buffered saline. The resulting bacte-
rial suspension was 1 × 109 CFU/ml. A sample of 1 mL of
this suspension was mixed in agarose and mineral oil
(Sigma Diagnoses, St Louis, USA) at 56°C. The resulting
oil-agar emulsion was cooled to obtain agar beads. Dilu-
tions of the final suspension were cultured to determine
the size of the final inoculum.
Experimental infection
Under a short general anesthesia with ether (Mallinkrodt,
Paris, France), with sterile surgical conditions, a small
midline incision was made on the neck ventral surface
after swabbing it with ethanol. The trachea was exposed
by blunt dissection. Using a 28-gauge needle, 0.1 mL of
agar beads followed by 0.5 mL of air were inoculated
intra-tracheally.
Quantitative bacteriological analysis
After exsanguination of the animal, the lungs were iso-
lated and homogenized in 2 mL of sterile isotonic saline.
Bacterial culture after serial dilutions was performed and
bacterial colonies counted after 12 h at 37°C.
Antimicrobial therapy
In a subgroup of animals, ceftazidime (GlaxoSmithKline,
Marly-le-Roi, France), 100 mg/kg, was administered in the
peritoneal cavity every 8 hours during 72 hours. Lungs
were harvested, homogenized and cultures were per-
formed to confirm bacterial eradication. Serum ceftazi-
dime levels were measured in HPLC.
Broncho-alveolar lavage (BAL)
Broncho-alveolar lavage (BAL) was performed by cannu-
lating the trachea. Lungs from each experimental group
were lavaged with a total of 20 ml in 5-ml aliquots of PBS
with EDTA (3 mM). BAL fluid samples were filtered and
immediately frozen at -80°C. A cell count was performed
directly. Cellular monolayers were prepared with a cyto-
centrifuge and stained with Wright-Giemsa stain. Cellular
morphotype differential was obtained by counting 200
cells/sample and expressing each type of cell as a percent-
age of the total number counted. Protein concentration in
the BAL was measured with an automated analyzer
(Hitachi 917, Japan).
Histological study
After a vascular flushing with sterile isotonic saline
through the pulmonary artery, the lungs were removed.
Samples were fixed by intratracheal instillation of parafor-
maldehyde 10 %. Samples were included in paraffin and
sections of 5 µm were realized. Analysis was performed
after coloration with Hematoxyline-Eosine-Safran (Zeiss,
LEO 906).
Serum and BAL TNF-α measurement
Levels of tumor necrosis factor α (TNF-α), in the serum,
and the BAL fluid, were determined by use of commercial
immunoassay kits (ELISA) specific for rat cytokines
(Quantikine Murine rat TNFα, R&D Systems, Abingdon
OX, UK). The reading was performed with a microplate
reader Digiscan (Spectracount Packard Instrument Com-
pany; Meriden CT USA).Respiratory Research 2005, 6:17 http://respiratory-research.com/content/6/1/17
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BAL and serum measurement of epinephrine and nor-
epinephrine
Blood and broncho-alveolar lavage fluid were collected
on heparin/Na-metabisulfite coated tubes. The samples
were centrifuged (2500 g, 4°C), supernatants were frozen
(-80°C).
Catecholamines are specifically fixed on alumina (pH =
8.7), the eluent is analyzed with an inversed phase
H.P.L.C (Coulochem II ESA). The results are expressed in
µg/L.
Functional study
Surgical preparation
Sprague-Dawley male rats were anesthetized with pento-
barbital (Sanofi, Libourne, France). A catheter (PE-50)
was inserted into the left carotid artery in order to monitor
systemic arterial pressure (Acqknowledge Software v
3.7.1, Biopac systems, Santa Barbara, CA, USA) and
obtain blood samples. An endotracheal tube (PE-220)
was inserted through a tracheostomy. The rats were venti-
lated with a constant volume pump (Harvard Apparatus,
South Natick, MA) with an inspired O2 fraction of 1.0, a
peak airway pressure of 8–12 cmH2O, and a positive end
expiratory pressure of 2 cmH2O. The animals were placed
in left decubitus position until the end of the protocol.
The body temperature was maintained at 37°C.
Preparation of the instillate
The test solution, used for alveolar instillation, was pre-
pared as follows : briefly, a 5% bovine albumin solution
was prepared using Ringer lactate and was adjusted with
NaCl to be isoosmolar with the rat circulating plasma
[13,14]. A sample of the instilled solution was saved for
total protein measurement, and water to dry weight ratio
measurements. In different experimental groups, terbuta-
line (10-4 M) (Sigma Aldrich, St Quentin Fallavier, France)
was added to the instillate or injected intra-peritoneally to
the animals.
General Protocol
For all ventilated rats experiments, the following general
protocol was used. After the surgical preparation, heart
rate and blood pressure were allowed to stabilize for 1
hour. To calculate the flux of plasma protein into the lung
interstitium, a vascular tracer, 1 µCi of 131I-labeled human
albumin, was injected into the bloodstream [14,15]. 131I-
HSA was prepared in our institution according to a stand-
ardized technique. Administration of the instillate (3 ml/
kg) was performed into the left lung over a 2-min period,
using a 1-ml syringe and polypropylene tube (PE 50,
Intramedic, Becton Dickinson, Sparks, MD, USA)[13].
One hour after the beginning of the alveolar instillation,
the rat was exanguinated. The lungs were removed, and
fluid from the distal airspaces was obtained (aspirate).
The total protein concentration and the radioactivity of
the liquid sampled were measured. Right and left lungs
were homogenized separately for water to dry weight ratio
measurements and radioactivity counts.
Measurements
• Hemodynamics, pulmonary gas exchange, and protein
concentration
Systemic arterial pressure and airway pressures were meas-
ured continuously. Arterial blood gases were measured at
one hour intervals. The arterial PO2 was used to quantify
the oxygenation deficit [13,14]. Samples from instillated
protein solution, final distal airspace fluid, and from ini-
tial and final blood were collected to measure total pro-
tein concentration with an automated analyzer (Hitachi
917, Japan).
• Albumin flux across endothelial and epithelial barriers
The flux of albumin across the lung endothelial and epi-
thelial barriers was used to evaluate the permeability. This
method requires measurement of the vascular protein
tracer,  131I-albumin, in the alveolar and extravascular
spaces of the lungs. Endothelial permeability was assessed
by measuring the ratio of 131-iodine radioactivity in the
aspirate to the radioactivity obtained in the plasma (Asp/
plasma), it reflects the leak of the vascular tracer in the
alveolar compartment. We estimated the quantity of
plasma that entered the instilled lungs by measuring the
transfer of the vascular protein tracer, 131I-albumin, into
the extravascular spaces of the instilled lung using the
equation of plasma equivalents previously described
[7,13,14].
• Extravascular lung water (EVLW) and lung liquid clear-
ance (LLC)
The EVLW was estimated by gravimetry: 300 µL of the
lung homogenate were weighed, to determine the wet
weight, and dessicated at 45°C during 7 days, to obtain
the dry weight. The blood fraction was calculated from the
homogenate hemoglobin supernatant content. The wet to
dry weight ratio (W/D) was estimated using the values of
the right lung which was not instilled [7,14,16]. Lung liq-
uid clearance was calculated as previously described [7].
• Distal Airspace Fluid Clearance (DAFC):
A change of native bovine albumin concentration over the
study period (1 h) was used to measure alveolar fluid
movement. DAFC was calculated from the ratio of the
final unlabeled alveolar protein concentration, compared
to the initial instilled alveolar protein concentration.Respiratory Research 2005, 6:17 http://respiratory-research.com/content/6/1/17
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Experimental groups
15 experimental groups were constituted for the study:
- A control group (Ctr), which received an intratracheal
instillation of sterile saline at the beginning of the
protocol
- 7 Sterile groups (St) received an intratracheal instillation
of sterile beads and were studied at different days after
inoculation: St 1, St 2, St 5, St 8, St 15, St 21 and St 28.
- 7 Pneumonic groups (Pn) received an intratracheal
instillation of Pseudomonas  containing beads and were
studied at different days after inoculation: Pn 1, Pn 2, Pn
5, Pn 8, Pn 15, Pn 21, Pn 28.
Statistical analysis
Comparisons between two groups were made using an
unpaired, two tailed Student's t-test. Comparisons
between more than two groups were made using a one
way analysis of variance with post hoc test for multiple
comparisons. A value of p < 0.05 was considered as signif-
icant. The data are expressed as means ± SD.
Results
Pseudomonas beads instillation is associated with the 
development of a chronic infection
Clinically, a major weight loss was observed from the sec-
ond day in P. aeruginosa beads infected animals compared
to the sterile beads groups (Figure 1). 5% of the infected
animals died within the first 48 hours after inoculation,
none did in the sterile groups.
Prior to the instillation, the size of the inoculum was 7.9
105 ± 1.5 105 CFU/mL. Lung bacterial load reached a peak
on the second day of the infection; from the 5th day, a pro-
gressive decrease occurred to finally remain steady
between the 15th day (8.25 ± 5.2 104 CFU/mL) and the 3rd
week (1.67 ± 1.63 105 CFU/mL).
Total broncho-alveolar lavage (BAL) cells slightly
increased in the sterile beads group, the difference was
however not statistically significant compared to the con-
trol group, the analysis showed that the number of cells
peaked on the second day and was constituted, at that
time, of 25% polymorphonuclear cells and 75% macro-
phages. The results were not statistically different over
time and therefore pooled in Table 1. In the infected
groups, alveolar cellularity was maximum on the 2nd day
mostly polymorphonuclear's neutrophils (PMN). From
the 8th day, the relative number of PMN progressively
decreased as alveolar macrophages increased. All the
results are summarized in Table 1.
Histologically, in the infected groups, from the 2nd day,
large numbers of PMNs were observed, mostly centered
on the alveoli (Figure 2C–D). Agar beads were clearly
observed in the Pn2 group (Figure 2D). With time,
increased extracellular material became more prominent
(Figure 2G–L). The lung architecture of animals inocu-
lated with sterile beads remained strictly normal (Figure
2A–B).
Table 1: Analysis of the bronchoalveolar lavage All the animals 
who received sterile beads were included in the sterile group and 
compared to the control and pneumonic groups at respectively 
2, 5, 8, 15 and 21 days post instillation.
Total cells (× 106)/mL PMNs (%) Macrophages (%)
Ctr 0.4 ± 0.1 0.5 ± 0.4 98.5 ± 0.5
St 3.2 ± 0.6 5.6 ± 4.4 92.9 ± 4.4
Pn 2 10.5 ± 2.9* 79.8 ± 5.2* 19.0 ± 4.6*
Pn 5 7.9 ± 1.7* 19.0 ± 8.0 79.3 ± 8.4
Pn 8 4.9 ± 1.0 3.8 ± 0.7 95.5 ± 1.0
Pn 15 4.0 ± 0.8 1.2 ± 0.6 98.8 ± 0.6
Pn 21 4.9 ± 1.8 2.0 ± 0.6 97.2 ± 0.6
Footnote: Data are mean (± SD). Comparisons between groups were 
made using analysis of variance with post hoc for multiple comparisons. 
*p < 0.05 vs the other groups.
PMNs: Polymorphonuclear neutrophils, Ctr: Control group, St: 
Sterile group, Pn: Pneumonic group
Evolution of animals' weight during the four weeks of the  analysis Figure 1
Evolution of animals' weight during the four weeks of the 
analysis. An initial weight loss is observed for the infected 
animals compared to the sterile beads group. Footnote: Data 
are mean (± SD). Comparisons between groups were made 
using analysis of variance. *p < 0.05 vs the Pn group. Pn: 
Pneumonic animals, St: animals which received only sterile 
beads
200
250
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400
450
D1 D2 D5 D8 D15 D21 D2
days
Weight (g)
8
St
Pn
*
*
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A transient increase of alveolar-capillary barrier 
permeability is observed on the second day post infection
No variation in permeability or clearance was observed
between St groups, so all the results were included in a sin-
gle group (St) for the analysis (at least 5 animals were
included in each time point). Alveolar-capillary barrier
permeability, evaluated by the leakage of the vascular
marker into the alveoli (Asp/plasma ratio), was increased
in infected animals on the second day compared to the
control group (0.59 ± 0.08 vs 0.11 ± 0.02). This ratio came
back to control values from the fifth to the 28th day. In the
St group a moderate but significant increase of the Asp/
plasma ratio was observed throughout the study (0.31 ±
0.04).
Both lung liquid clearance and DAFC increased on the 2nd 
day post infection; DAFC increase is not related to a TNF-
α or catecholamine dependent mechanism
• Extra-vascular lung water and Lung liquid clearance
(LLC)
As shown in Table 2, no difference in wet to dry lung
weight ratio was observed between the groups. LLC
increased in the pneumonic group on the second day after
Histological analysis of the different groups, controls and sterile beads instilled animals are compared to pneumonic rats from  the second to the 21st day post instillation Figure 2
Histological analysis of the different groups, controls and sterile beads instilled animals are compared to pneumonic rats from 
the second to the 21st day post instillation. Coloration was performed with Hematoxyline-Eosine-Safran. A: Control group; B: 
Sterile beads; C-D: Pneumonia on the 2nd day (the arrow on panel D underlines infected beads); E-F: Pneumonia on the 5th 
day; G-H: Pneumonia on the 8th day; I-J: Pneumonia on the 15th day; K-L: Pneumonia on the 21st day.Respiratory Research 2005, 6:17 http://respiratory-research.com/content/6/1/17
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the infection (p = 0.02) to return to baseline on the 5th
day. A moderate but not statistically significant increase
was observed in the Pn15 group (p = 0.13).
• Distal alveolar fluid clearance
Distal alveolar fluid clearance increased in the Pn2 group
(Figure 3). This ratio decreased back to baseline on the 5th
day and remained comparable to both the St and the Ctr
groups.
We tested whether the increase in DAFC observed at 48
hours was related to a TNF-α or a catecholamine depend-
ent mechanism. No TNF-α was detected between the 2nd
and 21st days in the serum or the alveolar compartment.
Similarly, neither epinephrine nor nor-epinephrine could
be detected in the alveolar compartment at 48 hours. The
levels recovered in the plasma were comparable between
control and pneumonic animals on the 2nd and the 5th
days (Table 3).
Distal airspace fluid clearance cannot be stimulated on the 
5th day post infection even after bacterial eradication
Even though DAFC returned to baseline values on the
fifth day post infection, alveolar function was not normal
in these chronically infected animals. First of all, since
bacterial load persisted in the alveoli at least a modest
increase of DAFC would have been expected in response
to this stimulus. This absence of the expected response led
us to test the DAFC response, in each group, to well
known pharmacological stimuli.
• Terbutaline
The administration of terbutaline is associated with an
increase in DAFC in controls. Stimulation with terbuta-
line intratracheally could not increase DAFC on the 5th
day post infection, the intraperitoneal injection also failed
to increase DAFC (Figure 4).
• Terbutaline after bacterial eradication
In order to eliminate the possibility of a direct bacterial
effect inhibiting the expected response in the chronically
infected animals, we performed a comparable stimulation
with terbutaline on 10 animals treated with ceftazidime
initiated 24 hours after the infection. On the 5th day, all
lungs were sterilized and measurement of ceftazidime lev-
els showed a steady state level at 46.3 ± 4.8 µg/mL.
Table 2: Lung liquid clearance (LLC) and lung wet to dry weight 
ratio (W/D). LLC increases on the second day post instillation 
and returns to baseline on the fifth day. W/D remains constant 
over time.
W/D LLC (%)
Ctr 4.33 ± 0.87 22.24 ± 3.65
St 4.29 ± 0.24 36.53 ± 4.95
Pn 2 4.66 ± 0.51 45.51 ± 4.26 *
Pn 5 4.03 ± 0.27 20.99 ± 5.94
Pn 8 3.47 ± 0.81 23.01 ± 2.80
Pn 15 3.92 ± 0.29 36.21 ± 8.23
Pn 21 4.31 ± 0.07 22.37 ± 2.56
Footnote: Data are mean (± SD). Comparisons between groups were 
made using analysis of variance with post hoc for multiple comparisons. 
*p < 0,05 vs the other groups.
Ctr: Control group, St: Sterile group, Pn: Pneumonic groups from 
the 2nd to the 21st days.
Table 3: Plasma catecholamines measurement Plasma 
catecholamines were measured in pneumonic animals on the 2nd 
and the 5th day post instillation compared to the control group. 
No statistically significant difference could be observed.
Ctr Pn2 Pn5
Epinephrine (µg/L) 8.5 ± 2.1 11.2 ± 4.9 14.2 ± 3.5
Norepinephrine (µg/L) 5.8 ± 0.8 7.0 ± 2.2 8.2 ± 1.9
Footnote: Data are mean (± SD). Comparisons between groups were 
made using analysis of variance with post hoc for multiple comparisons. 
Ctr: Control group, St: Sterile group, Pn: Pneumonic groups.
Evolution of the DAFC over time in sterile and infected  beads injected groups Figure 3
Evolution of the DAFC over time in sterile and infected 
beads injected groups. We observe an increase on the 2nd 
day post infection, the clearance returns to a basal level on 
the 5th day. Footnote: Data are mean (± SD). Comparisons 
between groups were made using analysis of variance with 
post hoc for multiple comparisons. *p < 0.05 vs the other 
groups. DAFC: distal alveolar fluid clearance, Ctr: Control 
group, St: sterile beads injected group, Pn: pneumonic 
groups from the 2nd to the 21st day.
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However, even after the eradication of the pathogen,
DAFC remained unresponsive to beta-adrenergic stimula-
tion (Figure 4).
Discussion
In our study we validated an experimental model allow-
ing us to explore alveolar function in chronic P. aeruginosa
lung infection through measurements of lung liquid
movements. In this model of chronic P. aeruginosa lung
infection, after observing an initial increase of both alveo-
lar permeability and lung fluid movements, we character-
ized an impairment of DAFC where, even though DAFC
returned to baseline, it remained unresponsive to phar-
macological stimuli.
In the first part of our work, we validated, on several
parameters, the chronic infection model previously
described by Cash et al [8]. After reaching a peak on the
second day of the infection and decreasing from the 5th to
the 15th day, lung bacterial load persisted for 3 weeks.
These results, as well as the analysis of the BAL and the
histological features, are consistent with the literature
[8,11,17,18].
Since, in this model, P. aeruginosa is associated with agar
beads, we performed, as control groups, instillation of
sterile agar beads. Sterile agar bead instilled rats did not
show any evidence of weight loss and although they did
present an increase in BAL cellularity, there were no
PMN's except a slight increase on the second day which
failed to reach a statistical significance (data not shown).
This result is consistent with the literature, Nacucchio et al
showed that agar beads alone could not reproduce the
same level of injury than P. aeruginosa in agar beads [19].
From this first part of our work, we concluded that the
model of chronic infection with P. aeruginosa is adequate,
based on clinical, bacteriological, cytological and histo-
logical data.
Although a clinical study has reported increased lung per-
meability in COPD patients infected by P. aeruginosa [20],
few studies have focused on the consequences of chronic
lung infection on alveolar function and particularly fluid
movements. In our study, lung fluid movements were
maximal on the 2nd day post infection. We observed an
increase of alveolar-capillary barrier permeability, DAFC
and overall lung liquid clearance. A normal lung wet to
dry weight ratio was a consequence of this adequate alve-
olar response. This contrasts sharply with the data we
obtained in an acute lung injury model where LLC dra-
matically decreased and W/D weight ratio increased at 4
and 24 hours after Pseudomonas instillation [7].
In our chronic model, following the increase in both per-
meability and lung liquid clearance, we observed an
improvement in permeability with a return to baseline of
these 2 parameters on the 5th day.
The St group presented a moderate increase in permeabil-
ity (Asp/plasma ratio: 0.31 ± 0.04), it has previously been
reported that agar beads could alone be responsible for a
moderate increase in permeability [19]. However, taking
into account the association of the other parameters
validating the model (clinical, bacteriological, cytological
and histological), this effect does not challenge the
model.
Our results showed an increase of the DAFC at 48 hours
post infection. In acute lung injury, the initial alveolar
Evaluation of DAFC in the control compared to the pneu- monic groups on the fifth day post instillation at baseline and  after stimulation with terbutaline Figure 4
Evaluation of DAFC in the control compared to the pneu-
monic groups on the fifth day post instillation at baseline and 
after stimulation with terbutaline. A last group received terb-
utaline after bacterial eradication with ceftazidime adminis-
tered intraperitoneally. None of the pneumonic groups could 
increase DAFC after either stimulation or bacterial eradica-
tion. Footnote: Data are mean (± SD). Comparisons between 
groups were made using analysis of variance with post hoc for 
multiple comparisons. *p < 0.05, statistically different from 
the control group. DAFC: distal alveolar fluid clearance. 
Ctr: Control group, Terbut: Control instilled with terbuta-
line (10-4 M), St + Terbut: Sterile beads instilled with terbu-
taline (10-4 M), Cefta + Terbut: Control group treated with 
ceftazidime (100 mg/kg/8 h for 72 h) and instilled with terbu-
taline (10-4 M), Pn5: Pneumonic group on the 5th day, Pn5 + 
Terbut: Pneumonic group on the 5th day instilled with terbu-
taline (10-4 M), Pn5 + Terbut IP: Pneumonic group on the 
5th day with an intraperitoneal injection of terbutaline, Pn5 + 
Cefta+ Terbut: Pneumonic group on the 5th day treated 
with ceftazidime (100 mg/kg/8 h for 72 h) instilled with terbu-
taline (10-4 M).
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response is usually towards an increase of DAFC which
many authors have documented in septic shock [21], or
after endotoxin administration [22]. In septic shock, this
increase was related to the release of endogenous catecho-
lamines. In acute P. aeruginosa pneumonia, increased
DAFC can be related to either Pseudomonas exoproducts
[15] or to a TNF-α dependent mechanism during the first
24 hours of the infection [4]. We tested in our model
whether TNF-α or catecholamines could explain our
results. TNF-α was not detectable and systemic endog-
enous epinephrine or nor-epinephrine not different from
controls on the 2nd or the 5th day. TNF-α is produced dur-
ing the early phase of pneumonia, and its short half life
probably explains the absence of detectable levels at 48
hours. A dynamic evaluation of TNF-α production with
serial samples or antibody neutralization experiments
would be helpful to precisely study the role of TNF-α. We
therefore did not rule out that TNF-α may have triggered
an inflammatory response which could be responsible for
the increased DAFC. Other potential mechanisms such as
Transforming Growth Factor β remain to be investigated
[23].
Surprisingly, on the fifth day, DAFC returned to baseline
along with the improvement in permeability. Although it
is logical to see an improvement in permeability, consist-
ent with a decrease of the bacterial burden and an ade-
quate host response, DAFC was expected to remain
increased. The persisting presence of the pathogen in the
alveoli and many factors only related to its presence
would normally lead to a persistent increase of DAFC
[15]. We therefore decided to evaluate if a normal increase
in DAFC could be elicited on the 5th day post infection in
response to known pharmacological stimuli [24,25]. In
the normal lung, intra-alveolar administration of terbuta-
line generates a DAFC increase of approximately 30%
[26]. We observed comparable results in our study in con-
trol animals as well as animals which received only sterile
beads. In our model, on the 5th day, terbutaline intratra-
chéal administration did not change DAFC. However the
lack of effect may be due to airway inflammation and an
inability to adequately deliver the drug, we therefore
decided to use intraperitoneal administration with the
same agent. Our results also show the absence of DAFC
increase. We then hypothesized that the absence of
response to the stimulation might be related to the persist-
ence of the pathogen in the alveoli. To test this hypothesis,
we injected the animals with ceftazidime to sterilize the
lungs on the 5th day. Sterilization was achieved but failed
to restore DAFC stimulation with terbutaline. To explain
this impairment of DAFC, different hypotheses still
remain to be investigated concerning these agonist's
receptors and their regulation. Other authors have shown
in different situations that either an internalization or a
decrease of affinity of the receptors [27] could be
observed. Another hypothesis could be a lost of sensitiza-
tion through a decrease of the AMPc dependent signal
transmission. It was shown, in vitro, on tracheal cells that
a continuous or repeated exposure to isoproterenol could
lead to a lost of sensitization [28].
If this unresponsiveness exists in patients, the absence of
an adapted DAFC response in chronic lung infection
could lead to major damage in the presence of any new
lung injury. Although chronic lung infection has not been
isolated, per se, as an aggravating factor associated to mor-
tality in COPD patients admitted in an intensive care unit,
a pre-existing underlying pathology is associated with a
worsening of the prognosis in community and nosoco-
mial pneumonia [29,30]. DAFC impairment might be
part of the answer to this effect of underlying disease.
In conclusion, chronic P. aeruginosa pneumonia is charac-
terized initially at 48 hours by an increased alveolar-capil-
lary barrier permeability and an adapted host response
with an increased DAFC and LLC preserving a normal
lung wet to dry weight ratio. On the 5th  day, DAFC
remains non responsive to pharmacological stimulation
even after bacterial elimination. This impairment of
DAFC could represent one of the factors responsible for
the increased susceptibility of chronically infected
patients to other respiratory insults.
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